This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Fx-1006A, tafamidis meglumine
Description: Fx-1006A stabilizes the protein transthyretin (TTR), preventing dissociation of the native TTR tetramer into monomers, resulting in the inhibition of TTR amyloid fibril formation. The dissociation of TTR is implicated in TTR amyloidosis.
Deal Structure: Tafamidis was originally developed by FoldRx.
In September 2010, Pfizer entered into an agreement to acquire FoldRx. Pfizer will make an upfront payment and contingent payments if certain milestones are achieved. Specific financial terms were not disclosed. The acquisition was completed in October 2010.
Additional information available to subscribers only: